IMPACT FACTOR 4.422 an Open Access Journal by MDPI Adjuvanted Influenza Vaccines Guest Editors: Message from the Guest Editors Dr. Eduardo Gomez-Casado One approach to improving influenza vaccines is to include Department of Biotechnology, adjuvants. An immunologic adjuvant is defined as a INIA-CSIC, 28040 Madrid, Spain substance that acts to accelerate, prolong, or enhance [email protected] antigen-specific immune responses when used in Dr. Dheeraj Soni combination with specific vaccine antigens. Adjuvants are Harvard Medical School, Boston particularly beneficial for influenza vaccines administered Children's Hospital, Boston, MA during a pandemic, when a rapid response is required or 02115, USA for use in patients with impaired immune responses. To Dheeraj.Soni@ date, six adjuvants have been used in licensed human childrens.harvard.edu vaccines: Alum, MF59, AS03, AF03, virosomes, and heat- labile enterotoxin (LT). This issue will address the potential of novel adjuvant Deadline for manuscript submissions: strategies to modulate innate and adaptive immune 20 February 2022 responses to facilitate the development of improved prophylactic or therapeutic vaccines. Submission of original articles and systematic reviews is welcome. Manuscripts will follow standard journal peer-review practices, and those accepted for publication will appear in the Special Issue, “Adjuvanted Influenza Vaccines”. We look forward to receiving and welcome your contributions. mdpi.com/si/68468 SpeciaIslsue IMPACT FACTOR 4.422 an Open Access Journal by MDPI Editor-in-Chief Message from the Editor-in-Chief Prof. Dr. Ralph A. Tripp Vaccines (ISSN 2076-393X) has had a 6-year history of Department of Infectious publishing peer-reviewed state of the art research that Diseases, College of Veterinary advances the knowledge of immunology in human disease Medicine, University of Georgia Athens, GA 30602-7387, USA protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health. Author Benefits Open Access:— free for readers, with article processing charges (APC) paid by authors or their institutions. High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and many other databases. Journal Rank: JCR - Q2 (Immunology) Contact Us Vaccines Tel: +41 61 683 77 34 mdpi.com/journal/vaccines MDPI, St. Alban-Anlage 66 Fax: +41 61 302 89 18 [email protected] 4052 Basel, Switzerland www.mdpi.com.